Sign In
Search Icon
Menu Icon

Threats, Capabilities, and Solutions

Public Health Emergency Medical Countermeasures Enterprise

ASPR engages federal and nonfederal partners through Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) activities to share information and coordinate plans and actions to ensure the nation has and can use medical countermeasures to protect Americans during disasters and emergencies resulting from known and unknown chemical, biological, radiological, or nuclear (CBRN) threats and emerging infectious diseases.


Threats Covered

Biological Threats

  • Bacillus anthracis (anthrax)* and multi-drug resistant B. anthracis (MDR anthrax)*
  • Burkholderia mallei (glanders)*
  • Burkholderia pseudomallei (melioidosis)*
  • Clostridium botulinum toxin (botulism)*
  • Ebola virus (Ebola disease)*
  • Emerging infectious diseases
  • Francisella tularensis (tularemia)*
  • Marburg virus (Marburg virus disease)*
  • Pandemic influenza
  • Rickettsia prowazekii (typhus)*
  • Severe acute respiratory syndrome-related coronavirus (SARS-CoV) (including SARS-CoV-1 and -2)*
  • Variola virus (smallpox)*
  • Yersinia pestis (plague)*

Chemical Threats

  • Acetylcholinesterase inhibitor nerve agents*
  • Chlorine
  • Cyanide salts – hydrogen, potassium, and sodium cyanide*
  • Pharmaceutical based agents (including opioids)*
  • Phosgene
  • Vesicants*

Radiological and Nuclear Threats

  • Radiological and nuclear agents*

Mission Capabilities

  • Early Research and Discovery
  • Advanced Research and Development
  • Manufacturing and Warm Base
  • Monitoring and Surveillance
  • Response Integration:​ Deployment, Distribution, Dispensing, Administration
  • Regulatory Science and Readiness
  • Supply Chain Resilience
  • Procurement and Stockpiling

Solution Space

  • Doctrine
  • Organization
  • Training
  • Leadership
  • Materiel
  • Facilities
  • Personnel
The Goal

Medical Countermeasure Preparedness to Mitigate Adverse Health Outcomes

* Indicates an identified material threat under section 319-2(c)(2)(A)(ii) of the Public Health Service Act, that, among other things, may make an MCM developer eligible to be awarded a material threat MCM priority review voucher pursuant to meeting the statutory criteria of 21 U.S.C. § 360bbb-4a.